United Therapeutics’ Remodulin Approved For Transition From GSK’s Flolan
This article was originally published in The Pink Sheet Daily
The expanded indication completes Remodulin’s accelerated approval requirements.
You may also be interested in...
United Therapeutics' promotional materials make misleading comparisons between Remodulin and GlaxoSmithKline's Flolan, FDA's ad review division says. The company says it discontinued the ads and requested doctors stop using the "Frequently Asked Questions" booklet in July 2004.
Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says